The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo,
budesonide and formoterol were evaluated in patients with moderate-to-severe chronic …

Salmeterol and formoterol are both β2‐agonist bronchodilators with a long duration of action
and are often classified together, yet they are distinctly different in their pharmacology …

Salmeterol and formoterol are two long-acting beta2-agonists for inhalation, currently being
used in clinical practice. The aim of the present study was to investigate the onset of action …

Background: Formoterol is a long-acting (≥ 12 hours) beta2-receptor agonist with a rapid
onset of action (1–3 minutes). It is approved in the United States, delivered via a single-dose …

Controversy over the use of inhaled β-ago-nists has dated almost from their introduction as a
treatment for asthma. Their effectiveness as bronchodilators is not disputed, but there is …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

Background. An effective, long-acting bronchodilator could benefit patients with asthma who
have symptoms not controlled by antiinflammatory drugs. We compared a new long-acting …

Background Use of short-acting β2-agonists in chronic obstructive pulmonary disease
(COPD) during treatment with long-acting β2-agonists is recommended as needed, but its …

Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a
partial agonist on the β2-receptor in comparison to formoterol. In the present study we …

Background. Asthma is characterized by hyperresponsiveness of the airways to
bronchoconstrictive stimuli. Long-acting β2-adrenoceptor agonists have been introduced as …